Optimizing oncolytic reovirus therapy in hepatocellular carcinoma: A single dose enhances immune modulation and tumor delivery
Open Access
- 7 August 2026
- journal article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (3)
Abstract
No abstract availableFunding Information
- Oncolytics Biotech
- Cancer Research UK
- Rosetrees Trust
- Guts UK
This publication has 10 references indexed in Scilit:
- Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinomaInternational Journal of Cancer, 2026
- For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough)Molecular Therapy, 2018
- The emerging role of oncolytic virus therapy against cancerChinese Clinical Oncology, 2018
- Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockadeScience Translational Medicine, 2018
- Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic VirusesMolecular Therapy, 2016
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T CellsThe Journal of Immunology, 2015
- Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in PatientsScience Translational Medicine, 2012
- Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingMolecular Cancer, 2011
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced CancerClinical Cancer Research, 2008
- HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerMolecular Therapy, 2005